Bleeding and non-bleeding phenotypes in patients with GGCX gene mutations

Thrombosis Research

Volumn 134, Issue 4, 2014, Pages 856-865

  Watzka, Matthias ^a   Geisen, Christof ^b   Scheer, Monika ^c   Wieland, Regina ^d   Wiegering, Verena ^e   Dörner, Thomas ^f   Laws, Hans Jürgen ^g   Gümrük, Fatma ^h   Hanalioglu, Sahin ^h   Ünal, Sule ^h   Albayrak, Davut ⁱ   Oldenburg, Johannes ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b University of Ulm   (Germany)

^c OLGAHOSPITAL   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h HACETTEPE UNIVERSITY   (Turkey)

ⁱ ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Bone; GGCX; MGP; Mutation; Osteocalcin

Indexed keywords

BLOOD CLOTTING FACTOR; OSTEOCALCIN; TRANSCRIPTION FACTOR RUNX2; VITAMIN K DEPENDENT CARBOXYLASE; VITAMIN K GROUP; GLUTAMYL CARBOXYLASE; LIGASE;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR DEFICIENCY; BONE MASS; CARBOXYLATION; CHILD; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HUMAN; INNER EAR HEARING LOSS; MALE; MIDDLE AGED; MIDFACE HYPOPLASIA; OSTEOPOROSIS; PHENOTYPE; PSEUDOXANTHOMA ELASTICUM; PULMONARY VALVE STENOSIS; SCHOOL CHILD; VALVULAR HEART DISEASE; VITAMIN K DEPENDENT BLOOD CLOTTING FACTOR DEFICIENCY; YOUNG ADULT; BLOOD; BLOOD CLOTTING DISORDER; BONE DENSITY; COMPLICATION; GENETICS; INFANT; METABOLISM; MUTATION; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; BLOOD COAGULATION DISORDERS, INHERITED; BLOOD COAGULATION FACTORS; BONE DENSITY; CARBON-CARBON LIGASES; CHILD; CHILD, PRESCHOOL; FEMALE; HEMORRHAGE; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; OSTEOCALCIN; PHENOTYPE; YOUNG ADULT;

EID: 84908207707     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.07.004     Document Type: Article

References (50)

1. Oldenburg J, Marinova M, Müller CR, Watzka M. The vitamin K cycle. Vitam Horm 2008;78:35-62.
2. Le Saux O, Urban Z, Tschuch C, Csiszar K, Bacchelli B, Quaglino D, et al.Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet 2000;25:223-7.
3. Nitschke Y, Baujat G, Botschen U,Wittkampf T, du Moulin M, Stella J, et al. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. Am J Hum Genet 2011;90:25-39.
4. Li Q, Grange DK, Armstrong NL,Whelan AJ, Hurley MY, Rishavy MA, et al. Mutations in the GGCX and ABCC6 genes in a family with pseudoxanthoma elasticum-like phenotypes. J Invest Dermatol 2009;129:553-63.
5. Vanakker OM, Martin L, Gheduzzi D, Leroy BP, Loeys BL, Guerci VI, et al. Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity. J Invest Dermatol 2007;127:581-7.
6. Zebboudj AF, Imura M, Bostrom K.Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002;277:4388-94.
7. Munroe PB, Olgunturk RO, Fryns JP, Van Maldergem L, Ziereisen F, Yuksel B, et al. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet 1999;21:142-4.
8. Hall JG. Embryopathy associated with oral anticoagulant therapy. Birth Defects Orig Artic Ser 1976;12:33-7.
9. Howe AM, Hawkins JK, Webster WS. The growth of the nasal septum in the 6-9 week period of foetal development-Warfarin embryopathy offers a new insight into prenatal facial development. Aust Dent J 2004;49:171-6.
10. Pettifor JM, Benson R. Congenital malformations associated with the administration of oral anticoagulants during pregnancy. J Pediatr 1975;86:459-62.
11. Marchetti G, Caruso P, Lunghi B, Pinotti M, Lapecorella M, Napolitano M, et al. Vitamin K-induced modification of coagulation phenotype in VKORC1 homozygous deficiency. J Thromb Haemost 2008;6:797-803.
12. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005;94:773-9.
13. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance andmultiple coagulation factor deficiency type 2. Nature 2004;427:537-41.
14. Watzka M, Westhofen P, Hass M, Marinova M, Potzsch B, Oldenburg J. Polymorphisms in VKORC1 and GGCX are not major genetic determinants of vitamin K-dependent coagulation factor activity in Western Germans. Thromb Haemost 2009;102:418-20.
15. Rost S, Geisen C, Fregin A, Seifried E, Muller CR, Oldenburg J. Founder mutation Arg485Pro led to recurrent compound heterozygous GGCX genotypes in two German patients with VKCFD type 1. Blood Coagul Fibrinolysis 2006;17:503-7.
16. Brenner B, Sanchez-Vega B, Wu SM, Lanir N, Stafford DW, Solera J. A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors. Blood 1998;92:4554-9.
17. Darghouth D, Hallgren KW, Odile I, Bazaa A, Berkner KL, Rosa JP, et al. Compound heterozygosity of a W493C substitution and R704/premature stop codon within the gamma-glutamyl carboxylase in combined vitamin K-dependent coagulation factor deficiency in a french family. Blood 2009;114:1302.
18. Darghouth D, Hallgren KW, Shtofman RL, Mrad A, Gharbi Y, Maherzi A, et al. Compound heterozygosity of novel missense mutations in the gamma-glutamyl-carboxylase gene causes hereditary combined vitamin K-dependent coagulation factor deficiency. Blood 2006;108:1925-31.
19. Li Q, Schurgers LJ, Smith AC, Tsokos M, Uitto J, Cowen EW. Co-existent pseudoxanthoma elasticum and vitaminK-dependent coagulation factor deficiency: compound heterozygosity for mutations in the GGCX gene. Am J Pathol 2009;174:534-40.
20. Lunghi B, Redaelli R, Caimi TM, Corno AR, Bernardi F, Marchetti G. Novel phenotype and gamma-glutamyl carboxylase mutations in combined deficiency of vitamin K-dependent coagulation factors. Haemophilia 2011;17:822-4.
21. Mousallem M, Spronk HM, Sacy R, Hakime N, Soute BA. Congenital combined deficiencies of all vitamin K-dependent coagulation factors. Thromb Haemost 2001;86:1334-6.
22. Rost S, Fregin A, Koch D, Compes M, Muller CR, Oldenburg J. Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors. Br J Haematol 2004;126:546-9.
23. Spronk HM, Farah RA, Buchanan GR, Vermeer C, Soute BA. Novel mutation in the gamma-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K-dependent blood coagulation factors. Blood 2000;96:3650-2.
24. Titapiwatanakun R, Rodriguez V, Middha S, Dukek BA, Pruthi RK. Novel splice site mutations in the gamma glutamyl carboxylase gene in a child with congenital combined deficiency of the vitamin K-dependent coagulation factors (VKCFD). Pediatr Blood Cancer 2009;53:92-5.
25. Lin PJ, Jin DY, Tie JK, Presnell SR, Straight DL, Stafford DW. The putative vitamin K-dependent gamma-glutamyl carboxylase internal propeptide appears to be the propeptide binding site. J Biol Chem 2002;277:28584-91.
26. Shimizu A, Sugiura I, Matsushita T, Kojima T, Hirai M, Saito H. Identification of the five hydrophilic residues (Lys-217, Lys-218, Arg-359, His-360, and Arg-513) essential for the structure and activity of vitamin K-dependent carboxylase. Biochem Biophys Res Commun 1998;251:22-6.
27. Soute BA, Jin DY, Spronk HM, Mutucumarana VP, Lin PJ, Hackeng TM, et al. Characteristics of recombinant W501S mutated human gamma-glutamyl carboxylase. J Thromb Haemost 2004;2:597-604.
28. Sugiura I, Furie B, Walsh CT, Furie BC. Profactor IX propeptide and glutamate substrate binding sites on the vitamin K-dependent carboxylase identified by site-directed mutagenesis. J Biol Chem 1996;271:17837-44.
29. Wu SM, Mutucumarana VP, Geromanos S, Stafford DW. The propeptide binding site of the bovine gamma-glutamyl carboxylase. J Biol Chem 1997;272:11718-22.
30. Yamada M, Kuliopulos A, Nelson NP, Roth DA, Furie B, Furie BC, et al. Localization of the factor IX propeptide binding site on recombinant vitamin K dependent carboxylase using benzoylphenylalanine photoaffinity peptide inactivators. Biochemistry 1995;34:481-9.
31. Mutucumarana VP, Stafford DW, Stanley TB, Jin DY, Solera J, Brenner B, et al. Expression and characterization of the naturally occurring mutation L394R in human gamma-glutamyl carboxylase. J Biol Chem 2000;275:32572-7.
32. Roth DA, Whirl ML, Velazquez-Estades LJ, Walsh CT, Furie B, Furie BC. Mutagenesis of vitamin K-dependent carboxylase demonstrates a carboxyl terminus-mediated interaction with vitamin K hydroquinone. J Biol Chem 1995;270:5305-11.
33. Pudota BN, Miyagi M, Hallgren KW, West KA, Crabb JW, Misono KS, et al. Identification of the vitamin K-dependent carboxylase active site: Cys-99 and Cys-450 are required for both epoxidation and carboxylation. Proc Natl Acad Sci U S A 2000;97:13033-8.
34. Rishavy MA, Hallgren KW, Yakubenko AV, Shtofman RL, Runge KW, Berkner KL. Bronsted analysis reveals Lys218 as the carboxylase active site base that deprotonates vitamin K hydroquinone to initiate vitamin K-dependent protein carboxylation. Biochemistry 2006;45:13239-48.
35. Shahin MH, Cavallari LH, Perera MA, Khalifa SI, Misher A, Langaee T, et al. VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thromb Haemost 2013;109:1045-50.
36. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93.
37. Gracia-Marco L, Vicente-Rodriguez G, Valtuena J, Rey-Lopez JP, Diaz Martinez AE, Mesana MI, et al. Bone mass and bone metabolism markers during adolescence: The HELENA Study. Horm Res Paediatr 2010;74:339-50.
38. Ivaska KK, Gerdhem P, Vaananen HK, Akesson K, Obrant KJ. Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res 2010;25:393-403.
39. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81.
40. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996;382:448-52.
41. Spohn G, Kleinridders A, Wunderlich FT, Watzka M, Zaucke F, Blumbach K, et al. VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding. Thromb Haemost 2009;101:1044-50.
42. Pauli RM. Mechanism of bone and cartilage maldevelopment in the warfarin embryopathy. Pathol Immunopathol Res 1988;7:107-12.
43. Coutu DL,Wu JH,Monette A, Rivard GE, BlosteinMD, Galipeau J. Periostin, amember of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells. J Biol Chem 2008;283:17991-8001.
44. Norris RA, Moreno-Rodriguez R, Hoffman S, Markwald RR. The many facets of the matricelluar protein periostin during cardiac development, remodeling, and pathophysiology. J Cell Commun Signal 2009;3:275-86.
45. Snider P, Hinton RB, Moreno-Rodriguez RA, Wang J, Rogers R, Lindsley A, et al. Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ Res 2008;102:752-60.
46. Snider P, Standley KN,Wang J, Azhar M, Doetschman T, Conway SJ. Origin of cardiac fibroblasts and the role of periostin. Circ Res 2009;105:934-47.
47. Walfisch A, Koren G. The "warfarin window" in pregnancy: the importance of half-life. J Obstet Gynaecol Can 2010;32:988-9.
48. Brunetti-Pierri N, Hunter JV, Boerkoel CF. Gray matter heterotopias and brachytelephalangic chondrodysplasia punctata: a complication of hyperemesis gravidarum induced vitamin K deficiency? Am J Med Genet A 2007;143:200-4.
49. Menger H, Lin AE, Toriello HV, Bernert G, Spranger JW. Vitamin K deficiency embryopathy: a phenocopy of the warfarin embryopathy due to a disorder of embryonic vitamin K metabolism. Am J Med Genet 1997;72:129-34.
50. Robinson JN, Banerjee R, Thiet MP. Coagulopathy secondary to vitamin K deficiency in hyperemesis gravidarum. Obstet Gynecol 1998;92:673-5.